Dermatology Times

Weekly Roundup: September 21-25

September 25, 2020

ICYMI, some of the content featured this week includes articles about how to choose a telemedicine vendor, the launch of an international COVID-19 dermatology registry, a study evaluating dupilumab’s durability versus cyclosporine in patients with atopic dermatitis, plus more.

AAD, NPF guidelines urge liver disease monitoring in psoriasis patients
Picosecond laser evaluated in melasma study
Cross-specialty collaboration key to tracking COVID-19 skin symptoms
Identifying dermatologic conditions in pediatric patients with COVID-19

First patient enrolled in vitiligo repigmentation study

September 23, 2020

AVITA Therapeutics has launched a study evaluating their RECELL System as a treatment for stable vitiligo.

How to choose a telemedicine vendor

September 22, 2020

With the increase in telemedicine use, physicians can (virtually) meet their patients’ needs now more than ever. However, with this swift increase in telehealth usage, how can physicians choose the best telemedicine vendor for their practice with so many options available?

FDA, EMA accepts marketing applications for bimekizumab in psoriasis

September 22, 2020

UCB announces the U.S. Food and Drug Administration and the European Medicines Agency have accepted the Biologics License Application and Marketing Authorization Application for bimekizumab for the treatment of moderate-to-severe plaque psoriasis in adults.

The science behind skin care for sensitive skin

September 22, 2020

The problem of sensitive skin has risen dramatically in the last decade, highlighting the need for affordable, effective and scientifically-formulated and tested products designed especially for people with sensitive skin.

The Mainstream Patient: September 21

September 21, 2020

This week’s edition of The Mainstream Patient features stories about dark circles, sun damage on different skin tones, wearing sunscreen with a mask, sleep’s effect on skin health, plus more.